Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
report (Date of earliest event reported): April 5, 2019
|
CORMEDIX
INC.
|
|
(Exact
Name of Registrant as Specified in Charter)
|
|
Delaware
|
001-34673
|
20-5894890
|
|
(State
or Other Jurisdictionof Incorporation)
|
(CommissionFile
Number)
|
(IRS
EmployerIdentification No.)
|
|
400
Connell Drive, Suite 5000, Berkeley Heights, NJ
|
07922
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code: (908) 517-9500
|
|
|
(Former
Name or Former Address, If Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01. Other Events.
On
Friday, April 5, 2019, the NYSE American notified us that we
had
regained compliance with the NYSE American listing requirements
because we resolved the continued listing deficiency with respect
to Section 1003(a)(i) (requiring
stockholders’ equity of $2.0 million or more if an issuer has
reported losses from continuing operations and/or net losses in two
of its three most recent fiscal years), Section 1003(a)(ii)
(requiring stockholders’ equity of $4.0 million or more if it
has reported losses from continuing operations and/or net losses in
three of its four most recent fiscal years), and Section
1003(a)(iii) (requiring stockholders’ equity of
$6.0 million or more if it
has reported losses from continuing operations and/or net losses in
its five most recent fiscal years) of the NYSE American Company
Guide.
We
previously reported that we had received a notice from the NYSE
American that, based on our Form 10-Q for the quarter ended March
31, 2018, filed on May 15, 2018 with the Securities and Exchange
Commission, we did not meet continued listing standards of the NYSE
American as set forth in Part 10 of the NYSE American Company
Guide.
A
copy of the press release we issued regarding this matter is
attached hereto as Exhibit 99.1 and is incorporated herein by
reference.
Item 9.01. Financial Statements and
Exhibits.
Press release dated
April 11, 2019.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
CORMEDIX
INC. |
|
|
|
|
|
|
|
Date: April 11,
2019
|
By:
|
/s/ Robert W.
Cook
|
|
|
|
Name:
|
Robert W.
Cook
|
|
|
|
Title:
|
Chief Financial
Officer
|
|